FS-2101

N/A

Report date: 2022/03/17 11:02:08

Base Information

Drug NameFS-2101
Drug Alias NameFS-2101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionCoronavirus spike glycoprotein inhibitors
TargetsCoronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Fosun Pharmaceutical (Group) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Fosun Pharmaceutical (Group) Co LtdShanghai Henlius Biotech Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A